evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 21 findings · 2 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 19%Low 13 · 61.9%Moderate 4 · 19%High 0 · 0%

Mesalamine vs placebo

Histological response · Patients with collagenous colitis

Mesalamine showed no clear difference in histological response compared with placebo (low certainty).

1 finding from 1 review

Mesalamine vs placebo

Withdrawals due to adverse events · Patients with collagenous colitis

Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Mesalamine vs placebo

Serious adverse events · Patients with collagenous colitis

Mesalamine showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Mesalamine vs sulfasalazine

Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease

It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).

2 findings from 1 review

Mesalamine (4 ‐ 4.5 g/day) vs budesonide

Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease

Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).

2 findings from 1 review

Delayed‐release mesalamine (3 ‐ 4.5 g/day) vs corticosteroids

Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease

Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).

5 findings from 1 review
Show 2 more findings

Controlled‐release mesalamine (1 ‐ 2 g/day) vs placebo

Decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease

Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in decrease in CDAI >=50, HBI >=2 or improvement/remission (as defined… compared with placebo (low certainty).

1 finding from 1 review

Controlled‐release mesalamine (1 ‐ 2 g/day) vs placebo

Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease

Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).

1 finding from 1 review

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission or clinical improvement ‐ Asacol (3.2 g/day) compared with placebo (very low certainty).

2 findings from 1 review

Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo

Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease

It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).

1 finding from 1 review